Hepatitis Research Today is a free monthly online journal that collates and summarizes the latest research about Hepatitis, including details on hepatitis a, b, c, causes, symptoms.

Volume 1 (2006), Issue 12 (December)

1. Distinct cellular responses differentiating alcohol- and hepatitis C virus-induced liver cirrhosis.
   Virol J, 3: 98. [Abstract] [Full-text]
2. Autoimmune liver disease and rheumatic manifestations.
   Curr Opin Rheumatol, 19(1): 74-80. [Abstract] [Full-text]
3. The prevalence and risk factors associated with esophageal varices in subjects with hepatitis C and advanced fibrosis.
   Gastrointest Endosc, 64(6): 855-64. [Abstract] [Full-text]
4. Present and future therapy for hepatitis C virus.
   Expert Rev Anti Infect Ther, 4(5): 781-93. [Abstract] [Full-text]
5. Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation.
   Liver Transpl, 12(12): 1805-12. [Abstract] [Full-text]
6. Liver transplantation for fulminant hepatitis related to nevirapine therapy.
   Liver Transpl, 12(12): 1880-2. [Abstract] [Full-text]
7. Genetic diversity of HCV genotype 2 strains in south western France.
   J Med Virol, 79(1): 26-34. [Abstract] [Full-text]
8. Comparison of hepatitis A and E virus infections among healthy children in Mongolia: evidence for infection with a subgenotype IA HAV in children.
   J Med Virol, 79(1): 18-25. [Abstract] [Full-text]
9. Analysis of the full-length genome of a subgenotype IIIB hepatitis A virus isolate: primers for broadly reactive PCR and genotypic analysis.
   J Med Virol, 79(1): 8-17. [Abstract] [Full-text]
10. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial.
    Hepatology, 44(6): 1675-84. [Abstract] [Full-text]
11. The protein kinase IKKepsilon can inhibit HCV expression independently of IFN and its own expression is downregulated in HCV-infected livers.
    Hepatology, 44(6): 1635-47. [Abstract] [Full-text]
12. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis.
    Hepatology, 44(6): 1543-54. [Abstract] [Full-text]
13. Intrahepatic virus-specific IL-10-producing CD8 T cells prevent liver damage during chronic hepatitis C virus infection.
    Hepatology, 44(6): 1607-16. [Abstract] [Full-text]
14. Cost-effectiveness of hematologic growth factors for anemia occurring during hepatitis C combination therapy.
    Hepatology, 44(6): 1598-606. [Abstract] [Full-text]
15. Fulminant hepatitis A virus infection in the United States: Incidence, prognosis, and outcomes.
    Hepatology, 44(6): 1589-97. [Abstract] [Full-text]
16. Entecavir resistance is rare in nucleoside naïve patients with hepatitis B.
    Hepatology, 44(6): 1656-65. [Abstract] [Full-text]
17. Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis.
    Hepatology, 44(6): 1648-55. [Abstract] [Full-text]
18. IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection.
    Hepatology, 44(6): 1617-25. [Abstract] [Full-text]
19. Clinical evaluation (Phase I) of a human monoclonal antibody against hepatitis C virus: safety and antiviral activity.
    J Hepatol, 46(1): 37-44. [Abstract] [Full-text]
20. Occult hepatitis B virus infection.
    J Hepatol, 46(1): 160-70. [Abstract] [Full-text]
21. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma.
    J Hepatol, 46(1): 45-52. [Abstract] [Full-text]
22. Rosiglitazone attenuates suppression of RXRalpha-dependent gene expression in inflamed liver.
    J Hepatol, 46(1): 115-23. [Abstract] [Full-text]
23. Antiviral therapy for hepatitis C virus--associated mixed cryoglobulinemia vasculitis: a long-term followup study.
    Arthritis Rheum, 54(11): 3696-706. [Abstract] [Full-text]
24. Outbreak of hepatitis C virus infection during sclerotherapy of varicose veins: long-term follow-up of 196 patients (4535 patient-years).
    J Hepatol, 46(1): 19-25. [Abstract] [Full-text]
25. Transient elastography for diagnosis of advanced fibrosis and portal hypertension in patients with hepatitis C recurrence after liver transplantation.
    Liver Transpl, 12(12): 1791-8. [Abstract] [Full-text]
26. Residual risk of HIV, HVB and HCV transmission by blood transfusion between 2002 and 2004 at the Abidjan National Blood Transfusion Center.
    Transfus Clin Biol, 13(4): 242-5. [Abstract] [Full-text]
27. Inhibition of hepatitis C IRES-mediated gene expression by small hairpin RNAs in human hepatocytes and mice.
    Ann N Y Acad Sci, 1082: 52-5. [Abstract] [Full-text]
28. Hepatitis C-associated granulomas after liver transplantation: morphologic spectrum and clinical implications.
    Am J Clin Pathol, 127(1): 128-34. [Abstract] [Full-text]
29. HBV and HCV infections and acute rejection differentially modulate CD95 and CD28 expression on peripheral blood lymphocytes after liver transplantation.
    Hum Immunol, 67(11): 884-93. [Abstract] [Full-text]
30. Hepatic histologic response (HR) to combination therapy among HCV/HIV-coinfected individuals: interferon induces HR independent of sustained virologic response (SVR).
    AIDS Res Hum Retroviruses, 22(11): 1091-8. [Abstract] [Full-text]
31. Negative-strand hepatitis C virus (HCV) RNA in peripheral blood mononuclear cells from anti-HCV-positive/HIV-infected women.
    J Infect Dis, 195(1): 124-33. [Abstract] [Full-text]
32. Hepatitis B virus genotypes in Alaska Native people with hepatocellular carcinoma: preponderance of genotype F.
    J Infect Dis, 195(1): 5-11. [Abstract] [Full-text]
33. Community-based seroepidemiological survey of hepatitis E virus infection in Catalonia, Spain.
    Clin Vaccine Immunol, 13(12): 1328-32. [Abstract] [Full-text]
34. Simultaneous quantification and genotyping of hepatitis B virus for genotypes A to G by real-time PCR and two-step melting curve analysis.
    J Clin Microbiol, 44(12): 4491-7. [Abstract] [Full-text]
35. Combined hepatitis C virus (HCV) antigen-antibody detection assay does not improve diagnosis for seronegative individuals with occult HCV infection.
    J Clin Microbiol, 44(12): 4559-60. [Abstract] [Full-text]
36. Increase in hepatitis C virus incidence in HIV-1-infected patients followed up since primary infection.
    Sex Transm Infect, 82(6): 458-60. [Abstract] [Full-text]
37. Infection rates in HIV-HCV patients treated with interferon are similar to those in HCV mono-infection and not related to neutropenia.
    HIV Clin Trials, 7(5): 251-4. [Abstract] [Full-text]
38. Liver fibrosis in HIV-infected patients with chronic hepatitis B extensively exposed to antiretroviral therapy with anti-HBV activity.
    HIV Clin Trials, 7(5): 246-50. [Abstract] [Full-text]
39. Rituximab therapy for Epstein-Barr virus-related chronic hepatitis following living donor kidney transplantation.
    Am J Kidney Dis, 48(6): 986-9. [Abstract] [Full-text]
40. Amoxicillin-clavulanic acid-induced hepatitis.
    Am J Otolaryngol, 28(1): 28-30. [Abstract] [Full-text]
41. Effect of seasonal variation on the clinical course of chronic hepatitis B.
    J Gastroenterol, 41(11): 1107-15. [Abstract] [Full-text]
42. Prognostic factors for hepatitis C recurrence in patients undergoing orthotopic liver transplantation.
    Transpl Immunol, 17(1): 47-50. [Abstract] [Full-text]
43. Blockade of TRAIL pathway ameliorates HBV-induced hepatocyte apoptosis in an acute hepatitis model.
    Biochem Biophys Res Commun, 352(2): 329-34. [Abstract] [Full-text]
44. Granulocyte macrophage colony-stimulating factor as an adjuvant for hepatitis B vaccination: a meta-analysis.
    Vaccine, 25(4): 709-18. [Abstract] [Full-text]
45. Hepatitis C viral infection is not associated with Waldenström's macroglobulinemia.
    Am J Hematol, 82(1): 83-4. [Abstract] [Full-text]
46. Long-term immunogenicity after single and booster dose of a live attenuated hepatitis A vaccine: results from 8-year follow-up.
    Vaccine, 25(3): 446-9. [Abstract] [Full-text]
47. Hepatitis A vaccination of Argentinean infants: comparison of two vaccination schedules.
    Vaccine, 25(1): 102-8. [Abstract] [Full-text]
48. Changes in plasma hormones profile and liver function in cows naturally exposed to lead and cadmium around different industrial areas.
    Res Vet Sci, 82(1): 16-21. [Abstract] [Full-text]
49. Molecular epidemiology of hepatitis B virus (HBV) genotypes and serotypes in patients with chronic HBV infection in Korea.
    Intervirology, 50(1): 52-7. [Abstract] [Full-text]
50. Intrahepatic mRNA levels of type I interferon receptor and interferon-stimulated genes in genotype 1b chronic hepatitis C. Association between IFNAR1 mRNA level and sustained response to interferon therapy.
    Intervirology, 50(1): 32-9. [Abstract] [Full-text]
51. Clinical characteristics of NonBNonC- HCC: Comparison with HBV and HCV related HCC.
    Intervirology, 50(1): 24-31. [Abstract] [Full-text]
52. Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C.
    Intervirology, 50(1): 16-23. [Abstract] [Full-text]
53. Low prevalence of anti-hepatitis C virus antibodies in Mexico: A systematic review.
    Intervirology, 50(1): 1-8. [Abstract] [Full-text]
54. Hepatitis C virus and liver transplantation.
    Clin Liver Dis, 10(4): 919-40. [Abstract] [Full-text]
55. Hepatitis C in transplant recipients of solid organs, other than liver.
    Clin Liver Dis, 10(4): 901-17. [Abstract] [Full-text]
56. New therapies in hepatitis C virus and chronic liver disease: antifibrotics.
    Clin Liver Dis, 10(4): 881-900. [Abstract] [Full-text]
57. New therapies: oral inhibitors and immune modulators.
    Clin Liver Dis, 10(4): 867-80. [Abstract] [Full-text]
58. Treatment of hepatitis C in special populations.
    Clin Liver Dis, 10(4): 851-65. [Abstract] [Full-text]
59. Optimizing treatment regimens in hepatitis C.
    Clin Liver Dis, 10(4): 835-50. [Abstract] [Full-text]
60. Diagnosis of hepatic fibrosis in patients with chronic hepatitis C.
    Clin Liver Dis, 10(4): 821-33. [Abstract] [Full-text]
61. Role of obesity, insulin resistance, and steatosis in hepatitis C virus infection.
    Clin Liver Dis, 10(4): 793-819. [Abstract] [Full-text]
62. Hepatitis C virus: virology and experimental systems.
    Clin Liver Dis, 10(4): 773-91. [Abstract] [Full-text]
63. HCV immunopathogenesis: virus-induced strategies against host immunity.
    Clin Liver Dis, 10(4): 753-71. [Abstract] [Full-text]
64. Chronic hepatitis C and screening for hepatocellular carcinoma.
    Clin Liver Dis, 10(4): 735-52. [Abstract] [Full-text]
65. The economics of hepatitis C virus.
    Clin Liver Dis, 10(4): 717-34. [Abstract] [Full-text]
66. The changing epidemiology and natural history of hepatitis C virus infection.
    Clin Liver Dis, 10(4): 697-715. [Abstract] [Full-text]
67. Distribution of hepatitis C virus genotypes in beta-thalassaemic patients from Northern India.
    Transfus Med, 16(6): 433-8. [Abstract] [Full-text]
68. Recombinant hepatitis C virus in experimentally infected chimpanzees.
    J Gen Virol, 88: 143-7. [Abstract] [Full-text]
69. Epidemic dynamics of two coexisting hepatitis C virus subtypes.
    J Gen Virol, 88: 123-33. [Abstract] [Full-text]
70. Hepatitis C in Australia: impact of a mass media campaign.
    Am J Prev Med, 31(6): 492-8. [Abstract] [Full-text]
71. Application of knowledge-driven spatial modelling approaches and uncertainty management to a study of Rift Valley fever in Africa.
    Int J Health Geogr, 5: 57. [Abstract] [Full-text]
72. Cohort effects in dynamic models and their impact on vaccination programmes: an example from hepatitis A.
    BMC Infect Dis, 6: 174. [Abstract] [Full-text]
73. Reactivation of an occult hepatitis B virus escape mutant in an anti-HBs positive, anti-HBc negative lymphoma patient.
    J Clin Virol, 38(1): 83-6. [Abstract] [Full-text]
74. Low-level liver enzyme elevations during HAART are not associated with liver fibrosis progression among HIV/HCV-coinfected patients.
    J Antimicrob Chemother, 59(1): 87-91. [Abstract] [Full-text]
75. Poor validity of self-reported HBV vaccination among young heroin users in Spain supports the policy "don't ask, draw a blood sample, vaccinate and try to schedule another visit".
    J Clin Virol, 38(1): 87-90. [Abstract] [Full-text]
76. A phage-displayed single chain variable fragment that interacts with hepatitis B core antigen: library construction, selection and diagnosis.
    J Clin Virol, 38(1): 49-56. [Abstract] [Full-text]
77. Seroprevalence of hepatitis E virus infection among institutionalized psychiatric patients in Taiwan.
    J Clin Virol, 38(1): 44-8. [Abstract] [Full-text]
78. Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy.
    J Clin Virol, 38(1): 32-8. [Abstract] [Full-text]
79. Rift Valley fever in West Africa: the role of space in endemicity.
    Trop Med Int Health, 11(12): 1878-88. [Abstract] [Full-text]
80. The clinical significance of early histological rejection with or without biochemical abnormality in adult living donor liver transplantation for hepatitis B virus related end stage liver disease.
    Transpl Int, 20(1): 37-44. [Abstract] [Full-text]
81. Analytical and clinical sensitivity of the Procleix Ultrio HIV-1/HCV/HBV assay in samples with a low viral load.
    Vox Sang, 92(1): 8-14. [Abstract] [Full-text]
82. Antibodies to a novel antigen in acute hepatitis C virus infections.
    Vox Sang, 92(1): 1-7. [Abstract] [Full-text]
83. Tamoxifen-induced non-alcoholic steatohepatitis: where are we now and where are we going?
    Expert Opin Drug Saf, 6(1): 1-4. [Abstract] [Full-text]
84. Therapeutic vaccination in chronic hepatitis B virus carriers.
    Expert Rev Vaccines, 5(5): 707-16. [Abstract] [Full-text]
85. Multicenter study on hepatitis C virus-related cryoglobulinemic glomerulonephritis.
    Am J Kidney Dis, 49(1): 69-82. [Abstract] [Full-text]
86. A 1-year study of the epidemiology of hepatitis A virus in Tunisia.
    Clin Microbiol Infect, 13(1): 25-32. [Abstract] [Full-text]
87. Prevalence and correlates of hepatitis C virus infection among street-recruited injection drug users in San Juan, Puerto Rico.
    J Urban Health, 83(6): 1105-13. [Abstract] [Full-text]
88. Rheumatologic manifestations of chronic hepatitis C infection.
    Joint Bone Spine, 73(6): 633-8. [Abstract] [Full-text]
89. Successful treatment of pediatric systemic polyarteritis nodosa with cholestatic hepatitis.
    Clin Rheumatol, 26(1): 122-4. [Abstract] [Full-text]
90. The anti-hepatitis drug DDB chemosensitizes multidrug resistant cancer cells in vitro and in vivo by inhibiting P-gp and enhancing apoptosis.
    Invest New Drugs, 25(2): 95-105. [Abstract] [Full-text]
91. Human immunodeficiency virus and hepatitis testing and prevalence among surgical patients in an urban university hospital.
    Am J Surg, 193(1): 55-60. [Abstract] [Full-text]
92. Liver resection for benign liver tumors: indications and outcome.
    Am J Surg, 193(1): 5-9. [Abstract] [Full-text]
93. Seroprevalence of Hepatitis-B infection amongst Taiwanese university students 18 years following the commencement of a national Hepatitis-B vaccination program.
    J Med Virol, 79(2): 138-43. [Abstract] [Full-text]
94. Hepatitis C Virus p7 membrane protein quasispecies variability in chronically infected patients treated with interferon and ribavirin, with or without amantadine.
    J Med Virol, 79(2): 144-54. [Abstract] [Full-text]
95. Dietary habits and nutrient intake in non-alcoholic steatohepatitis.
    Nutrition, 23(1): 46-52. [Abstract] [Full-text]
96. Polymorphisms of type I interferon receptor 1 promoter and their effects on chronic hepatitis B virus infection.
    J Hepatol, 46(2): 198-205. [Abstract] [Full-text]
97. Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study.
    J Hepatol, 46(2): 206-12. [Abstract] [Full-text]
98. Marked changes of the hepatic sinusoid in a transgenic mouse model of acute immune-mediated hepatitis.
    J Hepatol, 46(2): 239-46. [Abstract] [Full-text]
99. Prevention of severe toxic liver injury and oxidative stress in MCP-1-deficient mice.
    J Hepatol, 46(2): 230-8. [Abstract] [Full-text]
100. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years.
     Gastroenterology, 131(6): 1743-51. [Abstract] [Full-text]
101. Hepatitis C and risk of lymphoma: results of the European multicenter case-control study EPILYMPH.
     Gastroenterology, 131(6): 1879-86. [Abstract] [Full-text]
102. Overexpression of the gene for transmembrane 4 superfamily member 4 accelerates liver damage in rats treated with CCl4.
     J Hepatol, 46(2): 266-75. [Abstract] [Full-text]
103. Effects of lactitol on intestinal microflora and plasma endotoxin in patients with chronic viral hepatitis.
     J Infect, 54(1): 98-102. [Abstract] [Full-text]
104. A case of liver sarcoidosis mimicking cirrhosis.
     Clin Imaging, 31(1): 47-9. [Abstract] [Full-text]
105. The hepatoprotective activity of kinsenoside from Anoectochilus formosanus.
     Phytother Res, 21(1): 58-61. [Abstract] [Full-text]
106. Stable inhibition of hepatitis B virus expression and replication in HepG2.2.15 cells by RNA interference based on retrovirus delivery.
     J Biotechnol, 128(1): 32-40. [Abstract] [Full-text]
107. Expression profiling of peripheral-blood mononuclear cells from patients with chronic hepatitis C undergoing interferon therapy.
     J Infect Dis, 195(2): 255-67. [Abstract] [Full-text]
108. Mortality in siblings of patients coinfected with HIV and hepatitis C virus.
     J Infect Dis, 195(2): 230-5. [Abstract] [Full-text]
109. Aminotransferase elevation in HIV/hepatitis B virus co-infected patients treated with two active hepatitis B virus drugs.
     AIDS Patient Care STDS, 20(12): 817-22. [Abstract] [Full-text]
110. Hepatitis C virus eradication in intravenous drug users maintained with subcutaneous naltrexone implants.
     Hepatology, 45(1): 111-7. [Abstract] [Full-text]
111. Increasing dimethylarginine levels are associated with adverse clinical outcome in severe alcoholic hepatitis.
     Hepatology, 45(1): 62-71. [Abstract] [Full-text]
112. Uridine supplementation antagonizes zalcitabine-induced microvesicular steatohepatitis in mice.
     Hepatology, 45(1): 72-9. [Abstract] [Full-text]
113. A randomized controlled trial of lamivudine to treat acute hepatitis B.
     Hepatology, 45(1): 97-101. [Abstract] [Full-text]
114. Race, insulin resistance and hepatic steatosis in chronic hepatitis C.
     Hepatology, 45(1): 80-7. [Abstract] [Full-text]
115. Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein.
     Hepatology, 45(1): 102-10. [Abstract] [Full-text]
116. Role of immunoproteasome catalytic subunits in the immune response to hepatitis B virus.
     J Virol, 81(2): 483-91. [Abstract] [Full-text]
117. Bicistronic woodchuck hepatitis virus core and gamma interferon DNA vaccine can protect from hepatitis but does not elicit sterilizing antiviral immunity.
     J Virol, 81(2): 903-16. [Abstract] [Full-text]
118. Analysis of CD127 and KLRG1 expression on hepatitis C virus-specific CD8+ T cells reveals the existence of different memory T-cell subsets in the peripheral blood and liver.
     J Virol, 81(2): 945-53. [Abstract] [Full-text]
119. Genetic protection against hepatitis B virus conferred by CCR5Delta32: Evidence that CCR5 contributes to viral persistence.
     J Virol, 81(2): 441-5. [Abstract] [Full-text]
120. Impaired hepatitis C virus-specific T cell responses and recurrent hepatitis C virus in HIV coinfection.
     PLoS Med, 3(12): e492. [Abstract] [Full-text]

© 2006-2008 Hepatitis Research Today. All Rights Reserved.